Flagship explainer
What drives LIGAND PHARMACEUTICALS INC’s return on equity?
ROE is five filed business factors multiplied together.
| Input | Value | Fiscal year | Source |
|---|---|---|---|
| $124M | FY2025 |
| |
| Income before tax | $159M | FY2025 |
|
| Operating income | $41M | FY2025 |
|
| $268M | FY2025 |
| |
| Ending assets | $1.6B | FY2025 |
|
| Beginning assets | $942M | FY2024 |
|
| $1.0B | FY2025 |
| |
| $830M | FY2024 |
|
Source:
- SEC filingFiling detailsAccession 0000886163-26-000006